About This Video
ME Therapeutics Holdings Inc. CEO Salim Dhanji is joined by members of his team as they open the day's trading session on April 17th, 2024 from CSE HQ in Toronto, Canada.
ME Therapeutics Holdings Inc. began trading on the Canadian Securities Exchange on October 12, 2023 under the symbol CSE:METX
About the Company
ME Therapeutics is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. Their main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-tumour immunity.
Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe
STAY CONNECTED WITH THE CSE
=============================
- NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe
- PODCAST: https://blog.thecse.com/cse-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
- MAGAZINE: https://issuu.com/thecse/docs
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
together we will countdown to the market open and this would be followed by an interview with the company
executive Absol Dani I am the founder and CEO of me Therapeutics Holdings me Therapeutics Holdings is a preclinical stage biotechnology company that is developing drugs that overcome immune suppression to fight cancer we went public on the CC mainly for access to the capital markets and also liquidity for our shareholders we found that the csse provided a solid and reliable platform for a growth stage
company like ourselves we have an amazing team at me Therapeutics our directors John priel and Ken Harter are both professors at EMC we have Kim nji who is the a also a director who is the CEO of the publicly traded financial services company we have a really experienced public company CF follow with Ben Martin and we've surrounded ourselves with a lot of advisors and Consultants who are here to support us
we have a lot of exciting things coming down the pipeline We are continuing to ADV our drug development Pipeline and we're hoping to get closer to clinical trial by the end of the year we also just just closed $1.55 million financing which will help us get to that goal we are our most exciting recent Milestone was that we just completed $1.55 million
financing which is going to lead into helping us complete our future Milestones which is advancing our drug development program towards our first clinical trial by hopefully by the end of the year
More CSE Market Open
Ring the Bell for Financial Literacy 2026Oct 8, 2026

